Provider Briefing: Benzoyl Peroxide/Clindamycin Availability in 2026

If your patients have been reporting difficulty filling Benzoyl Peroxide/Clindamycin prescriptions, they're not alone. While this combination product is not on the FDA's official drug shortage list as of early 2026, intermittent availability issues at the pharmacy level have become a recurring concern — leading to treatment interruptions, patient frustration, and increased call volume for many dermatology and primary care practices.

This briefing covers the current supply landscape, prescribing implications, cost considerations, and practical tools you can use to support continuity of care for your acne patients.

Current Supply Timeline

Benzoyl Peroxide/Clindamycin has been available in the United States since its initial FDA approval in December 2000 (BenzaClin). Multiple formulations are currently marketed:

• BenzaClin — Clindamycin 1%/Benzoyl Peroxide 5% gel (requires refrigeration after mixing)
• Duac — Clindamycin 1%/Benzoyl Peroxide 5% gel (room temperature stable)
• Acanya — Clindamycin 1.2%/Benzoyl Peroxide 2.5% gel
• Onexton — Clindamycin 1.2%/Benzoyl Peroxide 3.75% gel
• Generic — Clindamycin 1.2%/Benzoyl Peroxide 5% gel (multiple manufacturers)

No formal shortage has been declared by the FDA or ASHP. However, localized supply disruptions have been reported, particularly for specific generic manufacturers. These disruptions appear to be driven by supply chain variability rather than raw material scarcity or regulatory issues.

Prescribing Implications

The intermittent availability issues create several practical challenges for prescribers:

Formulation-Specific Prescribing

Because the various formulations differ in strength (Benzoyl Peroxide concentrations range from 2.5% to 5%, and Clindamycin from 1% to 1.2%), pharmacists cannot automatically substitute one for another without prescriber authorization. When writing prescriptions, consider:

• Prescribing generically ("Clindamycin/Benzoyl Peroxide topical gel") with a note allowing pharmacist discretion on specific manufacturer or strength when clinically appropriate
• Including "may substitute" or "dispense as available" language where permitted by state law
• Writing for the most widely stocked formulation — the generic 1.2%/5% gel tends to have the broadest availability

Antibiotic Stewardship Considerations

Benzoyl Peroxide/Clindamycin remains a first-line topical therapy for inflammatory acne, in part because the Benzoyl Peroxide component mitigates the antibiotic resistance risk associated with topical Clindamycin monotherapy. When considering alternatives due to availability issues, prioritize regimens that maintain this resistance-prevention benefit:

• Adapalene/Benzoyl Peroxide (Epiduo, Epiduo Forte) eliminates the antibiotic entirely while maintaining Benzoyl Peroxide's antibacterial activity
• Cabtreo (Adapalene/Benzoyl Peroxide/Clindamycin) adds a retinoid to the existing combination — appropriate for moderate to severe cases
• Avoid prescribing topical Clindamycin alone as a substitute, as this increases resistance risk

Patient Communication

Patients who experience difficulty filling a prescription often interpret it as a shortage even when the issue is localized. Setting expectations upfront can reduce anxiety and call volume:

• Inform patients that availability may vary by pharmacy and that checking multiple locations is normal
• Recommend Medfinder for providers or direct patients to medfinder.com to check real-time pharmacy availability
• Provide an alternative prescription (or verbal authorization for the pharmacist to substitute) at the time of the initial visit to avoid callbacks

Availability Picture: What's on Pharmacy Shelves

Based on current supply data, here's a general picture of what's available:

• Generic Clindamycin/Benzoyl Peroxide 1.2%/5% gel: Most widely available formulation. Multiple manufacturers (Teva, Perrigo, Amneal, others). Intermittent stock-outs at chain pharmacies but generally findable.
• BenzaClin: Still available but less commonly stocked due to refrigeration requirement after mixing.
• Onexton: Brand-name product; availability is good but cost is prohibitive without insurance ($400+).
• Acanya: Available but less commonly stocked at some chains.
• Duac: Limited availability in the U.S. market.

Cost and Access Considerations

Affordability directly impacts whether patients can actually fill their prescriptions — even when stock is available:

• Generic (without insurance): $130–$215 per 45g tube at retail
• Generic (with discount coupons): $35–$80 via GoodRx, SingleCare, or similar services
• Brand-name products: $300–$600+ without insurance
• With commercial insurance: $15–$75 copay for generic (tier 2–3); brand names frequently require prior authorization or step therapy

For patients struggling with cost, several resources may help:

• Prescription discount cards (GoodRx, SingleCare, Optum Perks) — no insurance required
• Manufacturer copay assistance (Bausch Health programs for Onexton/Acanya — for eligible commercially insured patients)
• Prescription Hope ($70/month per medication for qualifying patients)
• NeedyMeds and RxAssist databases for patient assistance programs

For a patient-facing resource on savings, you can direct patients to our article on how to save money on Benzoyl Peroxide/Clindamycin.

Tools and Resources for Your Practice

Several tools can help you and your staff manage availability issues more efficiently:

Medfinder for Providers

Medfinder's provider platform allows you to check real-time pharmacy availability for Benzoyl Peroxide/Clindamycin by location. This can help front-desk staff direct patients to pharmacies that have stock, reducing callbacks and prescription transfer requests.

Electronic Prescribing Best Practices

• Use e-prescribing systems that allow you to check pharmacy inventory before sending the prescription
• Consider adding a second-choice pharmacy when sending prescriptions electronically
• Include notes allowing generic substitution across strengths when clinically appropriate

Pre-Visit Prescription Verification

For acne follow-up visits, have your staff verify prescription fill history. If a patient hasn't filled their Benzoyl Peroxide/Clindamycin in the expected timeframe, it may indicate an access problem worth addressing during the visit.

Looking Ahead

The topical acne treatment market continues to expand. The approval of Cabtreo in 2023 added a new triple-combination option, and several other pipeline products may further diversify the available options in the coming years. Generic competition for existing formulations is also expected to continue, which should improve long-term supply stability and affordability.

In the near term, the most effective strategy is proactive prescribing — writing for formulations with the broadest availability, empowering patients with tools to find stock, and having a ready alternative when needed.

Final Thoughts

Benzoyl Peroxide/Clindamycin remains a cornerstone of topical acne therapy, and the current availability challenges, while real, are manageable with the right approach. By prescribing flexibly, communicating proactively with patients, and leveraging tools like Medfinder for providers, you can minimize treatment disruptions and keep your patients' acne under control.

For the patient perspective on these issues, see our articles on why Benzoyl Peroxide/Clindamycin is hard to find and how patients can find it in stock.